Angela Zubel

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Eric Van Cutsem, Claus-Henning Köhne, István Láng et al. · Journal of Clinical Oncology · 2011 · 1.9K citations · Full text

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Carsten Bokemeyer, Igor Bondarenko, Anatoly Makhson et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Alberto Sobrero, Joan Maurel, Louis Fehrenbacher et al. · Journal of Clinical Oncology · 2008 · 945 citations · Full text

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann et al. · Annals of Oncology · 2011 · 778 citations · Full text

Biomarker Status, Oncology, Gastrointestinal Oncology +9

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Paolo A. Ascierto, Dirk Schadendorf, Carola Berking et al. · The Lancet Oncology · 2013 · 638 citations

Tumor Biology, Open-label Phase 2, Medicine +12